SOP Lungenarterienembolie

Die Lungenarterienembolie ist für klinisch tätige Ärzte von enormer Bedeutung. Schwerwiegende Verläufe dieses ernst zu nehmenden Krankheitsbildes, die bis hin zum Tode reichen, müssen verhindert werden. Der folgende Artikel gibt einen klar strukturierten sowie verständlichen Leitfaden an die Hand, der helfen soll, eine Lungenarterienembolie rasch zu erkennen, zu klassifizieren sowie adäquat zu behandeln.

Publication History

Article published online:
23 June 2023

• Literatur

• 1 Harjola VP, Mebazaa A, Čelutkienė J. et al. Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. Eur J Heart Fail 2016; 18: 226-241
• 2 Konstantinides SV, Meyer G, Becattini C. ESC Scientific Document Group. et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41: 543-603
• 3 Aujesky D, Obrosky DS, Stone RA. et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005; 172: 1041-1046
• 4 Jiménez D, Aujesky D, Moores L. RIETE Investigators. et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010; 170: 1383-1389
• 5 Bavalia R, Stals MAM, Mulder FI. et al. Use of the National Early Warning Score for predicting deterioration of patients with acute pulmonary embolism: a post-hoc analysis of the YEARS Study. Emerg Med J 2023; 40: 61-66
• 6 Mebazaa A, Tolppanen H, Mueller C. et al. Acute heart failure and cardiogenic shock: a multidisciplinary practical guidance. Intensive Care Med 2016; 42: 147-163
• 7 Thiele H, Ohman EM, Desch S. et al. Management of cardiogenic shock. Eur Heart J 2015; 36: 1223-1230
• 8 Wells PS, Anderson DR, Rodger M. et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 2000; 83: 416-420
• 9 Le Gal G, Righini M, Roy PM. et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med 2006; 144: 165-171
• 10 Provias T, Dudzinski DM, Jaff MR. et al. The Massachusetts General Hospital Pulmonary Embolism Response Team (MGH PERT): creation of a multidisciplinary program to improve care of patients with massive and submassive pulmonary embolism. Hosp Pract (1995) 2014; 42: 31-37
• 11 Bauersachs R, Berkowitz SD, Brenner B. EINSTEIN Investigators. et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510
• 12 Agnelli G, Buller HR, Cohen A. AMPLIFY Investigators. et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808
• 13 Büller HR, Décousus H, Grosso MA. Hokusai-VTE Investigators. et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406-1415
• 14 Schulman S, Kearon C, Kakkar AK. RE-COVER Study Group. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352
• 15 Meyer G, Vicaut E, Danays T. PEITHO Investigators. et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 2014; 370: 1402-1411
• 16 Weitz JI, Lensing AWA, Prins MH. EINSTEIN CHOICE Investigators. et al. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med 2017; 376: 1211-1222
• 17 Agnelli G, Buller HR, Cohen A. AMPLIFY-EXT Investigators. et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699-708